In terms of our 2021 production, there are two stages for mRNA vaccines. First there's a drug substance stage to make the mRNA. That is taking place in North Dakota, and we already have that space secured for us. This is at a facility that has a tremendous amount of experience. We've already tech transferred, so they know how to do what we need them to do to produce at scale.
The second part of that is done in Winnipeg, Manitoba, by Emergent BioSolutions. We are tech transferring to them this month so that they know how to do the formulation portion of the process, and then they do the fill-finish.
With just that existing capacity alone, once we start the process, the reason we could commit 50 million doses at that time is that we would be up and running. Assuming we had bought the raw materials in January, we could have been up and running in July and producing. That would have allowed us to make 50 million doses. We did not get the support for the raw materials. The soonest we could be up and running now would be in September. We could still make tens of millions of doses.
It's just there, waiting to be turned on.